Beatrice Linnea Christina Fagerang

Targeted complement inhibitors as novel therapeutic for diabetic
nephropathy

From left to right: Peter Garred, Beatrice Fageräng, Miroslava Bayarri and Rafael Bayarri Olmos

Applicant

Beatrice Linnea Christina Fagerang

Project description

Today, one in nine adults are living with diabetes. Despite our best efforts, up to 40% of them will develop a complication called diabetic nephropathy, a progressive and currently incurable kidney disease. An overactive immune response, particularly via the complement system, is emerging as a major, yet underexplored, contributor to chronic inflammation and kidney damage.

We have engineered a novel therapeutic designed to intervene precisely where it matters. Backed by strong in vitro data showing both targeting and inhibitory potential, our approach offers a new angle on treating complement-driven conditions, such as diabetic nephropathy.  

Through the SPARK program, we aim to generate in vivo proof-of-concept data and demonstrate that targeted complement modulation can become a transformative therapeutic strategy.

Institution

Copenhagen University Hospital

SPARK information

Beatrice and her team were accepted as part of cohort 5.